The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of postpartum haemorrhage. The sulphated glycosaminoglycans have a reduced anticoagulant activity and an antifactor IIa activity of less than 10IU/mg, an antifactor Xa activity of less than 10IU/mg and an average molecular weight (Mw) from about 4.6 to about 6.9kDa. The sulphated glucosaminolgycans are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels and cease the bleeding.
